Form 4: Humana CFO Susan Diamond Reports Stock Transactions
SEC Form 4 Filing
Humana's Chief Financial Officer, Susan Diamond, reported transactions involving company stock, including the disposition of shares and the holding of various derivative securities.
Summary
- Susan Diamond, the Chief Financial Officer of Humana Inc., filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
- The filing includes the disposition of 20,165 shares of Humana common stock.
- She also holds 2,219 shares indirectly through the Humana Retirement Savings Plan.
- The report details various stock options with different exercise prices and expiration dates, totaling 27,662 options.
- Diamond also holds 588 restricted stock units and 332 phantom stock units.
- The phantom stock units are held under the Humana Retirement Equalization Plan and fluctuate with the stock price.
- A transaction of 1 phantom stock unit was reported due to a quarterly dividend allocation.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock transactions by an executive, which is neither positive nor negative in itself. It is a neutral event.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common practice in publicly traded companies. It provides transparency into the executive's holdings and transactions.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, and Humana's filing is consistent with these requirements.
- The types of securities reported, including stock options, restricted stock units, and phantom stock units, are common forms of executive compensation in the healthcare industry.
- Companies like UnitedHealth Group (UNH) and CVS Health (CVS) also regularly report similar insider transactions.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the stock transactions of a key executive.
- The transactions do not have a direct impact on employees, customers, or suppliers.
Key Dates
| Date | Description |
|---|---|
| 02/22/2021 | Incentive and Non-Qualified stock options granted to reporting person, vesting in three annual increments from 2/22/22 to 2/22/24. |
| 08/01/2021 | Incentive and Non-Qualified stock options granted to reporting person, vesting in three annual increments from 8/1/22 to 8/1/24. |
| 02/21/2022 | Incentive and Non-Qualified stock options granted to reporting person, vesting in three annual increments from 2/21/23 to 2/21/25. |
| 02/24/2023 | Incentive and Non-Qualified stock options granted to reporting person, vesting in three annual increments from 2/24/24 to 2/24/26 and restricted stock units granted, 33% of the award is vesting on 12/15/23, 12/15/24, and 12/15/25. |
| 02/21/2024 | Incentive and Non-Qualified stock options granted to reporting person, vesting in three annual increments from 2/21/25 to 2/21/27. |
| 12/31/2024 | Date of the reported transactions, including the disposition of shares and the acquisition of phantom stock units due to dividend allocation. |
| 01/03/2025 | Date the Form 4 was signed. |
Keywords
Humana, stock options, Form 4, insider trading, Susan Diamond, restricted stock units, phantom stock units, executive compensation, stock ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.